^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zanzalintinib (XL092)

    i
    Other names: XL092, XL-092, XL 092
    Associations

    News

    Trials
    Company:
    Exelixis
    Drug class:
    c-MET inhibitor, Tyrosine kinase inhibitor, VEGFR-1 antagonist
    Related drugs:
    Associations

    News

    Trials
    10d
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Recruiting, University of Chicago | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    23d
    Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery (clinicaltrials.gov)
    P2, N=45, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2029 --> Oct 2030
    Trial completion date
    |
    zanzalintinib (XL092)
    1m
    LITESPARK-033: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) (clinicaltrials.gov)
    P3, N=904, Not yet recruiting, Merck Sharp & Dohme LLC
    New P3 trial
    |
    Cabometyx (cabozantinib tablet) • Welireg (belzutifan) • zanzalintinib (XL092)
    1m
    Maintenance Zanzalintinib With Etoposide After HDCT in GCT (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Indiana University | Not yet recruiting --> Recruiting | Trial completion date: Mar 2032 --> Sep 2031
    Enrollment open • Trial completion date
    |
    etoposide oral • zanzalintinib (XL092)
    1m
    Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov)
    P1/2, N=314, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Nov 2026 --> Nov 2025
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • docetaxel • Cotellic (cobimetinib) • pemetrexed • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Actemra IV (tocilizumab) • tiragolumab (RG6058) • Repatha (evolocumab) • camonsertib (RP-3500) • cibisatamab (RG7802) • ciforadenant (CPI-444) • zanzalintinib (XL092)
    1m
    Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) (clinicaltrials.gov)
    P1/2, N=140, Recruiting, Merck Sharp & Dohme LLC | N=100 --> 140
    Enrollment change
    |
    Keytruda (pembrolizumab) • Welireg (belzutifan) • zanzalintinib (XL092)
    2ms
    Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma (clinicaltrials.gov)
    P1, N=18, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Halaven (eribulin mesylate) • zanzalintinib (XL092)
    2ms
    Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial. (PubMed, Lancet)
    STELLAR-303 is the first phase 3 trial to show a significant improvement in overall survival with an immunotherapy-based regimen, zanzalintinib-atezolizumab, in patients with relapsed or refractory metastatic colorectal cancer that is not MSI-H or dMMR. This combination represents a chemotherapy-free treatment option with a novel mechanism of action for heavily pretreated patients in need of improved therapies.
    P3 data • Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)
    2ms
    STELLAR-303: Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=901, Active, not recruiting, Exelixis | Trial completion date: Feb 2026 --> Jan 2027 | Trial primary completion date: Aug 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR • RAS mutation
    |
    Tecentriq (atezolizumab) • Stivarga (regorafenib) • zanzalintinib (XL092)
    2ms
    Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, University of Chicago | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • zanzalintinib (XL092)
    2ms
    Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer (clinicaltrials.gov)
    P1, N=36, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • zanzalintinib (XL092)
    3ms
    A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    zanzalintinib (XL092)